Table 2 Characteristics of antipsychotic treatment (LAI versus LAI attributes)
Attribute | Level | Utility scores |
|---|---|---|
Frequency of administration and healthcare staff contact with patient | Once per 3Â weeks | +32.4 |
| Â | Once per 4Â weeks | +30.0 |
| Â | Once per 2Â weeks | 0 |
Side effects | Sedation | +200.6 |
| Â | Sexual side effects (prolactin) | +107.2 |
| Â | Weight gain of more than 7% of body mass | +102.6 |
| Â | Extrapyramidal side effect | +79.1 |
| Â | Metabolic side effects (diabetes, hypercholesterolaemia, dyslipidaemia) | +42.3 |
| Â | Tardive dyskinesia | 0 |
Pain at injection site | Absent | +158.8 |
| Â | Mild | +158.7 |
| Â | Moderate | +116.3 |
| Â | Severe | 0 |
Risk of embarrassment and potential harm to therapeutic relationship | Low risk | +118.6 |
| Â | High risk | 0 |
Routes of administration | Buttock muscle (gluteal) | +49.0 |
| Â | Deltoid muscle | +45.4 |
| Â | Ventro gluteal | 0 |